Paul Jeng – Guggenheim

Guggenheim

A Guggenheim analyst with 9 tracked ratings across 6 distinct tickers has a 3.0-star track record and achieved a perfect 100% success rate in the captured sample.

Aggregated from multiple market-data sources

Total ratings

Tickers covered

Sources

Aggregated

Latest rating

22 days ago

2026-05-13 00:00:00+00

Track record

Aggregated

No track record data

Bullish: 7
Hold: 0
Bearish: 0

Aggregated

75% success rate

Bullish: 0
Hold: 0
Bearish: 0

Aggregated

Not available

Bullish: 11
Hold: 1
Bearish: 0

Recent ratings

Ticker	Date	Rating	Price target	Source
CRBP	2026-05-13	buy	$45.00	Aggregated
IMTX	2026-05-12	buy	$19.00	Aggregated
CHRS	2026-05-11	buy	$12.00	Aggregated
CNTX	2026-05-06	buy	$5.00	Aggregated
CRBP	2026-04-29	buy	$45.00	Aggregated
CRBP	2026-04-28	buy	$45.00	Aggregated
IDYA	2026-04-14	buy	$54.00	Aggregated
IDYA	2026-04-13	buy	$54.00	Aggregated
ADAG	2026-04-06	buy	$10.00	Aggregated
CNTX	2026-03-24	buy	$5.00	Aggregated
IDYA	2026-02-18	buy	$50.00	Aggregated
ADAG	2025-11-24	buy	$9.00	Aggregated
IMTX	2025-11-18	buy	$19.00	Aggregated
IMTXIMMATICS N.V	2025-11-18	unknown	$19.00	Aggregated
CNTX	2025-09-18	buy	$5.00	Aggregated
CNTXCONTEXT THERAPEUTICS INC	2025-09-18	unknown	$5.00	Aggregated
IDYA	2025-09-18	buy	$50.00	Aggregated
IDYAIDEAYA BIOSCIENCES INC	2025-09-18	unknown	$50.00	Aggregated
IMCR	2025-09-18	hold	-	Aggregated
IMTX	2025-09-18	buy	$16.00	Aggregated
IMTXIMMATICS N.V	2025-09-18	unknown	$16.00	Aggregated

Tickers covered(10)

Ticker	Ratings	Last rating	Sources
CRBP	3	2026-05-13	Aggregated
IMTX	4	2026-05-12	Aggregated
CHRS	1	2026-05-11	Aggregated
CNTX	3	2026-05-06	Aggregated
IDYA	5	2026-04-14	Aggregated
ADAG	2	2026-04-06	Aggregated
IMTXIMMATICS N.V	3	2025-11-18	Aggregated
CNTXCONTEXT THERAPEUTICS INC	2	2025-09-18	Aggregated
IDYAIDEAYA BIOSCIENCES INC	2	2025-09-18	Aggregated
IMCR	1	2025-09-18	Aggregated

Methodology differs by source. Track records are aggregated from multiple sources; scoring methodology and scales differ by source and values are not directly comparable. Coverage is sourced from publicly-aggregated analyst activity. Past performance does not guarantee future results. Not investment advice.